[go: up one dir, main page]

MX2010002242A - Estimulación de ruta wnt en reprogramacion de celulas somaticas. - Google Patents

Estimulación de ruta wnt en reprogramacion de celulas somaticas.

Info

Publication number
MX2010002242A
MX2010002242A MX2010002242A MX2010002242A MX2010002242A MX 2010002242 A MX2010002242 A MX 2010002242A MX 2010002242 A MX2010002242 A MX 2010002242A MX 2010002242 A MX2010002242 A MX 2010002242A MX 2010002242 A MX2010002242 A MX 2010002242A
Authority
MX
Mexico
Prior art keywords
somatic cells
methods
reprogramming
reprogramming somatic
wnt pathway
Prior art date
Application number
MX2010002242A
Other languages
English (en)
Inventor
Rudolf Jaenisch
Ruth Foreman
Brett Chevalier
Alexander Marson
Richard A Young
Original Assignee
Whitehead Biomedical Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whitehead Biomedical Inst filed Critical Whitehead Biomedical Inst
Publication of MX2010002242A publication Critical patent/MX2010002242A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/602—Sox-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/604—Klf-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/45—Artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

La invención proporciona composiciones y métodos de uso en la reprogramación de células somáticas. Las composiciones y métodos de la invención son de uso, por ejemplo para generar o modular (por ejemplo, para mejorar) la generación de células madre pluripotentes inducidas al reprogramar células somáticas. Las células somáticas reprogramadas son útiles para varios propósitos, que incluyen tratar o prevenir una afección médica en un individuo. La invención proporciona además métodos para identificar un agente que reprograma células somáticas a un estado pluripotente y/o mejora la velocidad y/o eficiencia de la reprogramación. Ciertas composiciones y métodos se refieren a modular la ruta de Wnt.
MX2010002242A 2007-08-31 2008-08-29 Estimulación de ruta wnt en reprogramacion de celulas somaticas. MX2010002242A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96702807P 2007-08-31 2007-08-31
US18819008P 2008-08-06 2008-08-06
PCT/US2008/010249 WO2009032194A1 (en) 2007-08-31 2008-08-29 Wnt pathway stimulation in reprogramming somatic cells

Publications (1)

Publication Number Publication Date
MX2010002242A true MX2010002242A (es) 2010-06-01

Family

ID=40429192

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002242A MX2010002242A (es) 2007-08-31 2008-08-29 Estimulación de ruta wnt en reprogramacion de celulas somaticas.

Country Status (10)

Country Link
US (6) US9102919B2 (es)
EP (2) EP2198011B1 (es)
JP (8) JP6151879B2 (es)
CN (1) CN101855338B (es)
AU (5) AU2008297011B2 (es)
CA (2) CA2698091C (es)
ES (2) ES2799897T3 (es)
MX (1) MX2010002242A (es)
RU (1) RU2492232C2 (es)
WO (1) WO2009032194A1 (es)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7682828B2 (en) 2003-11-26 2010-03-23 Whitehead Institute For Biomedical Research Methods for reprogramming somatic cells
US20090227032A1 (en) 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
EP4223769A3 (en) 2005-12-13 2023-11-01 Kyoto University Nuclear reprogramming factor
US8129187B2 (en) 2005-12-13 2012-03-06 Kyoto University Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
JP5813321B2 (ja) 2007-03-23 2015-11-17 ウィスコンシン アラムニ リサーチ ファンデーション 体細胞の再プログラム化
EP3878949B1 (en) 2007-04-07 2025-06-04 Whitehead Institute for Biomedical Research Reprogramming of somatic cells
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
US9213999B2 (en) 2007-06-15 2015-12-15 Kyoto University Providing iPSCs to a customer
EP2198011B1 (en) 2007-08-31 2016-06-08 Whitehead Institute for Biomedical Research Wnt pathway stimulation in reprogramming somatic cells
EP2090649A1 (en) * 2008-02-13 2009-08-19 Fondazione Telethon Method for reprogramming differentiated cells
WO2009102983A2 (en) * 2008-02-15 2009-08-20 President And Fellows Of Harvard College Efficient induction of pluripotent stem cells using small molecule compounds
SG10201808863UA (en) 2008-03-17 2018-11-29 Scripps Research Inst Combined chemical and genetic approaches for generation of induced pluripotent stem cells
SG10201400329YA (en) 2008-05-02 2014-05-29 Univ Kyoto Method of nuclear reprogramming
DK2297307T3 (en) 2008-06-04 2016-07-25 Cellular Dynamics Int Inc PROCEDURES FOR THE MANUFACTURE OF IPS CELLS USING NON-VIRAL METHODS
CA2727681C (en) 2008-06-13 2017-07-25 Whitehead Institute For Biomedical Research Programming and reprogramming of cells
CN107988261A (zh) 2008-08-12 2018-05-04 细胞动力国际有限公司 产生ips细胞的方法
WO2010068955A2 (en) * 2008-12-13 2010-06-17 Dna Microarray MICROENVIRONMENT NICHE ASSAY FOR CiPS SCREENING
EP2373784B1 (en) 2008-12-17 2017-10-25 The Scripps Research Institute Generation and maintenance of stem cells
DK2432881T3 (en) 2009-05-18 2018-02-26 Curna Inc TREATMENT OF REPROGRAMMING FACTOR-RELATED DISEASES BY INHIBITING NATURAL ANTISENSE TRANSCRIPTS TO A REPROGRAMMING FACTOR
EP3150701B1 (en) * 2009-06-05 2018-10-03 FUJIFILM Cellular Dynamics, Inc. Reprogramming t cells and hematopoietic cells
JP2011004674A (ja) * 2009-06-26 2011-01-13 Fujitsu Ltd 誘導多能性幹細胞（ｉＰＳ細胞）の製造方法
SG177552A1 (en) 2009-07-08 2012-03-29 Inst Nat Sante Rech Med A method for inducing extended self-renewal of functionally differentiated somatic cells
JP5886195B2 (ja) 2009-07-09 2016-03-16 ホワイトヘッド・インスティチュート・フォア・バイオメディカル・リサーチ 哺乳動物遺伝学のための組成物および方法、ならびにその使用
JP5751548B2 (ja) * 2009-08-07 2015-07-22 国立大学法人京都大学 イヌｉＰＳ細胞及びその製造方法
CN102741394B (zh) 2009-10-16 2016-05-04 斯克里普斯研究所 多能细胞的诱导
KR102014977B1 (ko) 2009-10-31 2019-08-27 뉴 월드 레보러토리즈 인코포레이티드. 세포의 재프로그램화 방법 및 이의 용도
US9453205B2 (en) 2009-10-31 2016-09-27 Genesis Technologies Limited Methods for reprogramming cells and uses thereof
US20140038291A1 (en) 2009-10-31 2014-02-06 New World Laboratories Inc. Methods for reprogramming cells and uses thereof
JP5898086B2 (ja) * 2009-11-04 2016-04-06 セルラー ダイナミクス インターナショナル， インコーポレイテッド 化学物質を用いるエピソームリプログラミング
JP2013510563A (ja) * 2009-11-13 2013-03-28 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 操作された微小胞を用いた真核細胞のリプログラミング
CN105176930B (zh) 2010-03-31 2021-05-04 斯克里普斯研究所 重编程细胞
ES2986590T3 (es) 2010-06-14 2024-11-12 Scripps Research Inst Reprogramación de células hacia un nuevo destino
JPWO2011158852A1 (ja) * 2010-06-15 2013-08-19 国立大学法人 東京大学 誘導型多能性幹細胞の製造方法
KR101975688B1 (ko) 2010-12-22 2019-05-07 페이트 세러퓨틱스, 인코포레이티드 단세포 분류 및 iPSC의 증강된 재프로그래밍을 위한 세포 배양 플랫폼
US9926532B2 (en) 2010-12-31 2018-03-27 Guangzhou Institute Of Biomedicine And Health Method of generating induced pluripotent stem cells and differentiated cells
CN107988381B (zh) 2011-07-25 2021-05-28 国立大学法人京都大学 筛选诱导的多能干细胞的方法
EP2763670B1 (en) * 2011-10-03 2018-12-05 Universite Libre De Bruxelles Reactivation of hiv-1 gene expression to treat persistent hiv infection
JP6162604B2 (ja) 2011-10-21 2017-07-12 国立大学法人京都大学 層流による多能性維持単一分散細胞培養法
JP5999658B2 (ja) 2011-11-25 2016-09-28 国立大学法人京都大学 多能性幹細胞の培養方法
RU2477314C1 (ru) * 2011-12-07 2013-03-10 Федеральное государственное бюджетное учреждение "Новосибирский научно-исследовательский институт патологии кровообращения имени академика Е.Н. Мешалкина" Минздравсоцразвития РФ, (ФГБУ "ННИИПК им. акад. Е.Н. Мешалкина" Минздравсоцразвития России) РЕКОМБИНАНТНАЯ ПЛАЗМИДА pSM-ZsGreen, КОДИРУЮЩАЯ БЕЛКИ SOX2 И С-MYC ЧЕЛОВЕКА И ФЛУОРЕСЦЕНТНЫЙ БЕЛОК ZsGreen, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ПОЛУЧЕНИЯ ИНДУЦИРОВАННЫХ ПЛЮРИПОТЕНТНЫХ СТВОЛОВЫХ КЛЕТОК ЧЕЛОВЕКА
WO2013159103A1 (en) * 2012-04-20 2013-10-24 Whitehead Institute For Biomedical Research Programming and reprogramming of cells
US10077429B2 (en) 2012-10-23 2018-09-18 Kyoto University Method of efficiently establishing induced pluripotent stem cells
WO2014123242A1 (ja) 2013-02-08 2014-08-14 国立大学法人京都大学 巨核球及び血小板の製造方法
JP6292415B2 (ja) 2013-03-06 2018-03-14 国立大学法人京都大学 多能性幹細胞の培養システム及び多能性幹細胞の継代方法
CN105247070A (zh) 2013-03-15 2016-01-13 怀特黑德生物医学研究院 用于神经变性疾病的细胞性发现平台
US10519421B2 (en) 2013-03-21 2019-12-31 Kyoto University Induction of motor neurons from pluripotent stem cells
WO2014157257A1 (ja) 2013-03-25 2014-10-02 公益財団法人先端医療振興財団 細胞の選別方法
CA2909230C (en) 2013-04-12 2021-06-15 Kyoto University Method for inducing alveolar epithelial progenitor cells
JP6429280B2 (ja) 2013-05-14 2018-11-28 国立大学法人京都大学 効率的な心筋細胞の誘導方法
CN105247041B (zh) 2013-05-31 2018-04-20 爱心细胞有限公司 组入有水凝胶的层叠细胞膜片
WO2014200115A1 (ja) 2013-06-11 2014-12-18 国立大学法人京都大学 腎前駆細胞の製造方法及び腎前駆細胞を含む医薬
US9796962B2 (en) 2013-08-07 2017-10-24 Kyoto University Method for generating pancreatic hormone-producing cells
US11473058B2 (en) 2013-09-05 2022-10-18 Kyoto University Method for inducing dopaminergic neuron progenitor cells
KR102219743B1 (ko) 2013-11-01 2021-02-23 고쿠리츠 다이가쿠 호진 교토 다이가쿠 신규 연골 세포 유도 방법
ES2966757T3 (es) 2014-03-04 2024-04-24 Fate Therapeutics Inc Métodos de reprogramación mejorados y plataformas de cultivo celular
WO2015140257A1 (en) 2014-03-19 2015-09-24 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for inducing human cholangiocyte differentiation
EP3929302A1 (en) 2014-07-14 2021-12-29 Chugai Seiyaku Kabushiki Kaisha Method for identifying epitope on protein
KR102654784B1 (ko) 2014-07-18 2024-04-04 사이아스 가부시키가이샤 다능성 줄기세포로부터 세포-기반 면역요법용 t 세포를 유도하는 방법
EP3191578B1 (en) 2014-09-12 2020-11-04 Whitehead Institute for Biomedical Research Cells expressing apolipoprotein e and uses thereof
WO2016104717A1 (ja) 2014-12-26 2016-06-30 国立大学法人京都大学 肝細胞誘導方法
CA2974903A1 (en) 2015-01-26 2016-08-04 Fate Therapeutics, Inc. Cells with increased immuno-regulatory properties and methods for their use and manufacture
US10561687B2 (en) 2015-02-17 2020-02-18 University Health Network Methods for making and using sinoatrial node-like pacemaker cardiomyocytes and ventricular-like cardiomyocytes
EP3081638A1 (en) 2015-04-16 2016-10-19 Kyoto University Method for producing pseudo-islets
RU2621547C2 (ru) * 2015-06-26 2017-06-06 Андрей Степанович БРЮХОВЕЦКИЙ Способ дистанционной мультиволновой электромагнитной радионейроинженерии головного мозга человека
JP2018520688A (ja) 2015-07-21 2018-08-02 ザ チルドレンズ メディカル センター コーポレーション Ｐｄ−ｌ１発現造血幹細胞およびその使用
SG11201802957PA (en) 2015-10-16 2018-05-30 Fate Therapeutics Inc Platform for the induction & maintenance of ground state pluripotency
PL3444334T3 (pl) 2016-04-15 2022-01-10 Kyoto University Sposób indukowania limfocytów t cd8-dodatnich swoistych wobec antygenu
JP7011260B2 (ja) 2016-04-22 2022-02-10 国立大学法人京都大学 ドーパミン産生神経前駆細胞の製造方法
US11352605B2 (en) 2016-05-12 2022-06-07 Erasmus University Medical Center Rotterdam Method for culturing myogenic cells, cultures obtained therefrom, screening methods, and cell culture medium
WO2018064460A1 (en) * 2016-09-30 2018-04-05 Mayo Foundation For Medical Education And Research Viral vectors for nuclear reprogramming
KR102537361B1 (ko) 2016-12-27 2023-05-26 스미또모 가가꾸 가부시키가이샤 인공 다능성 줄기 세포의 평가 방법 및 선발 방법, 그리고 인공 다능성 줄기 세포의 제조 방법
EP4053268B1 (en) 2017-01-20 2025-10-08 Kyoto University Method for producing cd8alpha+beta+cytotoxic t cells
JP7162537B2 (ja) 2017-01-26 2022-10-28 国立大学法人大阪大学 幹細胞の中胚葉系細胞への分化誘導用培地および中胚葉系細胞の製造方法
JP7171055B2 (ja) 2017-03-14 2022-11-15 国立大学法人京都大学 多能性幹細胞からヘルパーｔ細胞を製造する方法
CN110662832B (zh) 2017-05-25 2024-01-05 国立大学法人京都大学 由间介中胚层细胞分化诱导肾祖细胞的方法和由多能干细胞分化诱导肾祖细胞的方法
JP6758631B2 (ja) 2017-06-19 2020-09-23 国立大学法人大阪大学 角膜内皮細胞マーカー及びその利用
WO2018235583A1 (ja) 2017-06-19 2018-12-27 公益財団法人神戸医療産業都市推進機構 多能性幹細胞の分化能の予測方法及びそのための試薬
NL2019517B1 (en) 2017-09-08 2019-03-19 Univ Erasmus Med Ct Rotterdam New therapy for Pompe disease
WO2019060708A1 (en) 2017-09-22 2019-03-28 The Children's Medical Center Corporation TREATMENT OF TYPE 1 DIABETES AND AUTOIMMUNE DISEASES OR DISORDERS
JP7140400B2 (ja) 2017-10-17 2022-09-21 国立大学法人京都大学 多能性幹細胞から人工神経筋接合部を得る方法
SG11202100260QA (en) 2018-07-13 2021-02-25 Univ Kyoto METHOD FOR PRODUCING γδ T CELLS
EP3824912A4 (en) 2018-07-19 2022-04-20 Kyoto University PLATEFORM CARTILAGE DERIVED FROM PLURIPOTENTS STEM CELLS AND METHODS FOR PRODUCTION OF PLATEFORM CARTILAGE
WO2020022261A1 (ja) 2018-07-23 2020-01-30 国立大学法人京都大学 新規腎前駆細胞マーカーおよびそれを利用した腎前駆細胞の濃縮方法
EP3892722A4 (en) 2018-12-06 2022-10-05 Kirin Holdings Kabushiki Kaisha Production method for t cells or nk cells, medium for culturing t cells or nk cells, method for culturing t cells or nk cells, method for maintaining undifferentiated state of undifferentiated t cells, and growth-accelerating agent for t cells or nk cells
JP7224001B2 (ja) 2018-12-21 2023-02-17 国立大学法人京都大学 ルブリシン局在軟骨様組織、その製造方法及びそれを含む関節軟骨損傷治療用組成物
JP7637379B2 (ja) 2018-12-26 2025-02-28 キリンホールディングス株式会社 改変ｔｃｒ及びその製造方法
JP2022535192A (ja) 2019-05-14 2022-08-05 アレフ ファームス リミテッド 多能性細胞凝集体およびそれらの使用
WO2020235319A1 (ja) 2019-05-20 2020-11-26 味の素株式会社 軟骨又は骨の前駆細胞の拡大培養方法
CN115003795B (zh) * 2019-11-14 2025-03-11 岛崎猛夫 细胞的重编程方法
WO2021117886A1 (ja) 2019-12-12 2021-06-17 国立大学法人千葉大学 巨核球および血小板を含む凍結乾燥製剤
JP7778708B2 (ja) 2020-02-28 2025-12-02 武田薬品工業株式会社 多能性幹細胞からナチュラルキラー細胞を産生するための方法
EP3922431A1 (en) 2020-06-08 2021-12-15 Erasmus University Medical Center Rotterdam Method of manufacturing microdevices for lab-on-chip applications
US20230257705A1 (en) 2020-06-17 2023-08-17 Kyoto University Chimeric antigen receptor-expressing immunocompetent cells
WO2022014604A1 (ja) 2020-07-13 2022-01-20 国立大学法人京都大学 骨格筋前駆細胞及びその精製方法、筋原性疾患を治療するための組成物、並びに骨格筋前駆細胞を含む細胞群の製造方法
EP3940704A1 (en) * 2020-07-14 2022-01-19 Koninklijke Philips N.V. Method for determining the differentiation state of a stem cell
EP4180514A4 (en) 2020-07-20 2024-09-04 Aichi Medical University COMPOSITION FOR UNDIFFERENTIATED MAINTENANCE CULTURE OF PLURIPOTENT CELLS, MEDIUM FOR UNDIFFERENTIATED MAINTENANCE CULTURE OF PLURIPOTENT CELLS, METHOD FOR MAINTENANCE CULTURE IN UNDIFFERENTIATED STATE OF PLURIPOTENT CELLS, AND METHOD FOR PRODUCING PLURIPOTENT CELLS
EP4202041A4 (en) 2020-08-18 2024-10-16 Kyoto University Method for maintaining and amplifying human primordial germ cells / human primordial germ cell-like cells
MX2023005491A (es) 2020-11-24 2023-08-09 Lyell Immunopharma Inc Métodos de preparación de células t rejuvenecidas, composiciones que las comprenden y métodos de uso de las mismas.
US20240182858A1 (en) 2021-03-17 2024-06-06 Astellas Pharma Inc. Pericyte having basic fibroblast growth factor (bfgf) gene introduced therein
AU2022266430A1 (en) 2021-04-30 2023-12-14 Riken Cord-like aggregates of retinal pigment epithelial cells, device and production method for producing same, and therapeutic agent comprising said cord-like aggregates
JPWO2022255489A1 (es) 2021-06-04 2022-12-08
WO2022259721A1 (ja) 2021-06-10 2022-12-15 味の素株式会社 間葉系幹細胞の製造方法
MX2023014979A (es) 2021-06-15 2024-02-09 Takeda Pharmaceuticals Co Metodo para producir linfocitos citoliticos naturales a partir de celulas madre pluripotentes.
US20240335480A1 (en) 2021-07-15 2024-10-10 Astellas Pharma Inc. Vascular endothelial growth factor (vegf)-highly expressing pericyte-like cell
WO2023286832A1 (ja) 2021-07-15 2023-01-19 アステラス製薬株式会社 血管内皮増殖因子（ｖｅｇｆ）高発現ペリサイト様細胞の製造方法
WO2023017848A1 (ja) 2021-08-11 2023-02-16 国立大学法人京都大学 腎間質前駆細胞の製造方法並びにエリスロポエチン産生細胞、およびレニン産生細胞の製造方法
US20250041418A1 (en) 2021-11-11 2025-02-06 Healios K.K. Gene-modified pluripotent stem cell, immunocompetent cell derived therefrom, method for producing said cells, and use thereof
CA3251557A1 (en) 2022-02-09 2025-03-03 Kyoto University METHOD FOR EVALUATING THE DIFFERENTIATION POTENTIAL OF CELLS IN A CULTURE BROTH IN THE DIFFERENCE OF MULTIPOTENTED STEM CELLS INTO NEURAL CELLS OF THE MENSCEPHAL FLOOR PLAQUE REGION
EP4516905A1 (en) 2022-04-27 2025-03-05 Kyoto University Epicardial cell regeneration promoter and method for promoting epicardial cell regeneration
US20250376727A1 (en) 2022-06-10 2025-12-11 Kyoto University Detection method and detection reagent for undifferentiated pluripotent stem cells
WO2024248023A1 (ja) 2023-05-29 2024-12-05 京都府公立大学法人 視交叉上核オルガノイドの製造方法
WO2024248017A1 (ja) 2023-05-29 2024-12-05 国立研究開発法人理化学研究所 心筋細胞を成熟させる方法及び成熟した心筋細胞の製造方法
CN121195060A (zh) 2023-05-31 2025-12-23 学校法人顺天堂 源自多能干细胞的cd4阳性t细胞、其制造方法以及其用途

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
US5698446A (en) 1994-09-07 1997-12-16 Chiron Corporation Methods and compositions for inhibiting production of replication competent virus
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5712171A (en) 1995-01-20 1998-01-27 Arqule, Inc. Method of generating a plurality of chemical compounds in a spatially arranged array
US6057117A (en) 1996-04-04 2000-05-02 Chiron Corporation Identification and use of selective inhibitors of glycogen synthase kinase 3
US20010012513A1 (en) 1996-08-19 2001-08-09 University Of Massachusetts Embryonic or stem-like cell lines produced by cross species nuclear transplantation
WO2000027998A2 (en) 1998-11-11 2000-05-18 Emory University Method and compositions for improving allogeneic hematopoietic cell transplantation
IL129966A (en) 1999-05-14 2009-12-24 Technion Res & Dev Foundation ISOLATED HUMAN EMBRYOID BODIES (hEB) DERIVED FROM HUMAN EMBRYONIC STEM CELLS
EP1106180B1 (en) 1999-12-08 2003-11-12 Centre National de la Recherche Scientifique (CNRS) Use of hymenialdisine or derivatives thereof in the manufacture of medicaments
US6608063B2 (en) 1999-12-17 2003-08-19 Chiron Corporation Pyrazine based inhibitors of glycogen synthase kinase 3
FR2804959B1 (fr) 2000-02-15 2006-04-28 Centre Nat Rech Scient Utilisation de derives de paullones pour la fabrication de medicaments
US20040087016A1 (en) * 2000-05-12 2004-05-06 University Of Utah Research Foundation Compositions and methods for cell dedifferentiation and tissue regeneration
WO2002085909A1 (en) 2001-04-20 2002-10-31 Vertex Pharmaceuticals Incorporated 9-deazaguanine derivatives as inhibitors of gsk-3
CA2450683A1 (en) * 2001-07-16 2003-01-30 Edwards Lifesciences Corporation Tissue engineered heart valve
US6916798B2 (en) 2001-08-03 2005-07-12 Vertex Pharmaceuticals Incorporated Inhibitors of GSK-3 and uses thereof
ATE466581T1 (de) 2001-12-07 2010-05-15 Vertex Pharma Verbindungen auf pyrimidin-basis als gsk-3-hemmer
CA2476214A1 (en) 2002-02-08 2003-08-14 University Of South Florida Proliferated cell lines and uses thereof
US6835810B2 (en) 2002-05-13 2004-12-28 Geneshuttle Biopharma, Inc. Fusion protein for use as vector
WO2004018419A2 (en) 2002-08-23 2004-03-04 Chiron Corporation Benzimidazole quinolinones and uses thereof
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7153832B2 (en) 2003-04-07 2006-12-26 The Board Of Trustees Of The Leland Stanford Junior University Compositions of active Wnt protein
KR20060056377A (ko) 2003-08-13 2006-05-24 카이론 코포레이션 Ｇｓｋ-3 억제제 및 그것의 사용
US7682828B2 (en) 2003-11-26 2010-03-23 Whitehead Institute For Biomedical Research Methods for reprogramming somatic cells
US20060030042A1 (en) * 2003-12-19 2006-02-09 Ali Brivanlou Maintenance of embryonic stem cells by the GSK-3 inhibitor 6-bromoindirubin-3'-oxime
JP4901471B2 (ja) * 2004-02-19 2012-03-21 国立大学法人京都大学 体細胞核初期化物質のスクリーニング方法
EP1574499A1 (en) 2004-03-08 2005-09-14 DKFZ Deutsches Krebsforschungszentrum Inhibitors of DNA methylation in tumor cells
US7850960B2 (en) 2004-12-30 2010-12-14 University Of Washington Methods for regulation of stem cells
WO2006091737A1 (en) 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
WO2007007054A1 (en) 2005-07-08 2007-01-18 Cancer Research Technology Limited Phthalamides, succinimides and related compounds and their use as pharmaceuticals
JP2009517085A (ja) 2005-11-28 2009-04-30 チョンウェ ファーマ コーポレイション 培養における細胞の無血清増殖
EP4223769A3 (en) 2005-12-13 2023-11-01 Kyoto University Nuclear reprogramming factor
US8278104B2 (en) * 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
WO2007113505A2 (en) 2006-03-30 2007-10-11 The University Court Of The University Of Edinburgh Culture medium containing kinase inhibitors. and uses thereof
GB0615327D0 (en) 2006-03-30 2006-09-13 Univ Edinburgh Culture medium containing kinase inhibitors and uses thereof
EP3878949B1 (en) 2007-04-07 2025-06-04 Whitehead Institute for Biomedical Research Reprogramming of somatic cells
EP2198011B1 (en) * 2007-08-31 2016-06-08 Whitehead Institute for Biomedical Research Wnt pathway stimulation in reprogramming somatic cells
WO2009101407A2 (en) 2008-02-11 2009-08-20 Cambridge Enterprise Limited Improved reprogramming of mammalian cells, and the cells obtained
CA2727681C (en) 2008-06-13 2017-07-25 Whitehead Institute For Biomedical Research Programming and reprogramming of cells
US20120034192A1 (en) 2008-09-19 2012-02-09 Young Richard A Compositions and methods for enhancing cell reprogramming
EP2421956A4 (en) 2009-04-24 2013-10-02 Whitehead Biomedical Inst COMPOSITIONS AND METHODS FOR OBTAINING OR CULTURING PLURIPOTENTER CELLS

Also Published As

Publication number Publication date
US20230279359A1 (en) 2023-09-07
EP2198011B1 (en) 2016-06-08
ES2589122T3 (es) 2016-11-10
EP2198011A4 (en) 2010-09-08
AU2017239605B2 (en) 2019-11-07
US9593311B2 (en) 2017-03-14
CA3006367A1 (en) 2009-03-12
AU2017239605A1 (en) 2017-10-26
JP2017140054A (ja) 2017-08-17
JP7377309B2 (ja) 2023-11-09
US9102919B2 (en) 2015-08-11
JP6151879B2 (ja) 2017-06-21
US20170218341A1 (en) 2017-08-03
EP3078738B1 (en) 2020-05-20
JP2022087314A (ja) 2022-06-09
CA2698091A1 (en) 2009-03-12
AU2020200825B2 (en) 2022-09-29
JP2010537634A (ja) 2010-12-09
US20100310525A1 (en) 2010-12-09
US20190284537A1 (en) 2019-09-19
CA2698091C (en) 2018-07-03
AU2008297011A1 (en) 2009-03-12
AU2014224119A1 (en) 2014-10-02
JP2016171818A (ja) 2016-09-29
AU2020200825A1 (en) 2020-02-20
JP2024100852A (ja) 2024-07-26
RU2492232C2 (ru) 2013-09-10
CN101855338A (zh) 2010-10-06
EP3078738A1 (en) 2016-10-12
JP2019115358A (ja) 2019-07-18
WO2009032194A1 (en) 2009-03-12
AU2014224119B2 (en) 2017-08-03
ES2799897T3 (es) 2020-12-22
AU2008297011B2 (en) 2014-06-12
JP6470233B2 (ja) 2019-02-13
USRE49281E1 (en) 2022-11-08
AU2022291621B2 (en) 2026-01-15
JP2022087313A (ja) 2022-06-09
RU2010112393A (ru) 2011-10-10
EP2198011A1 (en) 2010-06-23
US20160068819A1 (en) 2016-03-10
CN101855338B (zh) 2013-07-17
JP2014087373A (ja) 2014-05-15
AU2022291621A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
MX2010002242A (es) Estimulación de ruta wnt en reprogramacion de celulas somaticas.
ES2544967T3 (es) Formulación y método para la prevención y el tratamiento de las metástasis óseas o de otras enfermedades óseas
WO2010033920A3 (en) Compositions and methods for enhancing cell reprogramming
BRPI0921726B8 (pt) método para preparar uma composição de implante para promover o crescimento ósseo em um mamífero
MX2009004986A (es) Metodos de tratamiento de anemia hemolitica.
AR061816A1 (es) Una nueva cepa de trichoderma atroviride, un medio de cultivo conteniendola, asi como la utilizacion de dicha cepa en particular como estimulante de la germinacion y/o del crecimiento de las plantas
MY159971A (en) Multipotent/pluripotent cells and methods
UY31816A (es) Agente para el tratamiento y/o prevención de una enfemedad autoinmune y para la formación de células t reguladoras
BRPI0409363A (pt) métodos e meios para o aumento da toleráncia de plantas a condições de tensão
AR048411A1 (es) Metodos para controlar patogenos de plantas que utilizan n-fosfonometilglicina
PE20151982A1 (es) Derivados de bencimidazolona como inhibidores del bromodominio
PE20110358A1 (es) Metodos y composiciones para el tratamiento de defectos oseos con poblaciones de celulas placentarias
MX2017003452A (es) Composiciones que comprenden celulas recombinantes de bacillus y otro agente de control biologico.
CL2015001973A1 (es) (divisional de la sol. 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos.
CY1120115T1 (el) Προερχομενα απο μυελο των οστων μεσεγχυματικα αρχεγονα κυτταρα ως μια πηγη νευρικων προγονων
AR079500A1 (es) Uso combinado de proteinas cry1ca y cry1fa para el manejo de la resistencia de insectos
ECSP099699A (es) Derivados de 4-aza indol y su uso como fungicidas
AR049723A1 (es) Sustancias activas para el aumento de la defensa frente a patogenos en plantas y metodos para su deteccion
ECSP10010372A (es) Métodos y composiciones que utilizan polipéptidos de fusión de klotho-fgf
DK1866324T3 (da) Phosphoramidatderivater af nukleosidforbindelser til anvendelse i behandlingen af cancer
CL2011000209A1 (es) Composicion biocida que comprende ciprodinil y piribencarb; metodo para controlar enfermedades en plantas utiles o en material de propagacion causadas por fitopatogenos (div. sol. n° 2602-06).
CL2007003452A1 (es) Metodo para prevenir enfermedades de plantas causadas por microorganismos, fitopatogenos, que comprende aplicar la quinolina 3-(5-fluor-3,3-dimetil-3,4-dehidroisoquinolin-1-il)quinolina en tratamiento directo a las semillas.
CU24048B1 (es) Composiciones para tratar náusea y vómito centralmente mediados
UY36332A (es) Composiciones de bacillus pumilus rt1279 y metodos de uso para benefficiar el crecimiento de las plantas
CA2983434C (en) Nkt-cell subset for in vivo persistence and therapeutic activity and propagation of same

Legal Events

Date Code Title Description
FG Grant or registration